Chapter 106 Sepsis
INTRODUCTION
Sepsis, severe sepsis, and septic shock (see Chapter 107) are common causes of morbidity and mortality. The incidence of severe sepsis in humans in the United States is approximately 3 cases per 1000; the mortality rate is approximately 30% and is due to progression to septic shock and multiple organ failure.1 The incidence of sepsis in veterinary medicine is unknown, but the mortality rates appear to be similar, ranging from 20% to 68%.2-6 Recognition and early, aggressive intervention and supportive care are key to the treatment of sepsis and septic shock.
DEFINITIONS
DIAGNOSTIC CRITERIA FOR SEPSIS
Sepsis and the systemic inflammatory response syndrome(SIRS) are clinical syndromes, not diseases, and as such are inherently difficult to define. In 2001, the International Sepsis Definitions Conference produced consensus guidelines for definitions and terminology for syndromes associated with microbial infection and the host response to it.7 Because of the difficulty in defining universal physiologic derangements associated with sepsis, the Consensus Committee produced a list of clinical and physiologic derangements to “attempt to codify the physical and laboratory findings that prompt an experienced clinician to conclude that an infected patient ‘looks septic’”7 (Box 106-1). These criteria were proposed for human patients. Therefore, although conceptually useful for veterinary patients, specific values have not been validated in these species.
STAGING SEPSIS
Following the 2001 International Sepsis Definitions Conference, the concept called PIRO was adopted to stage sepsis and to describe clinical manifestations of the infection and the host response to it.7 In this model, PIRO is an acronym for predisposition, insult or infection, response, and organ dysfunction. This conceptual and clinical framework attempts to incorporate patient factors with the microbial insult in order to stage the disease process and to identify factors that may contribute to morbidity and mortality. The PIRO approach may employ advanced diagnostic techniques not yet available in veterinary medicine, but hopefully it can serve as a guideline until similar methods are available and validated (Table 106-1).
PIRO | Present | Future |
---|---|---|
Predisposition | Age, species, gender, breed, concurrent illness | Genetic susceptibility of the host to an abnormal or inappropriate inflammatory response and enhanced understanding of the host response to infection |
Insult or infection | Culture and sensitivity of infecting organisms | Detection of microbial products (e.g., LPS, bacterial DNA) |
Response | SIRS, clinical and clinicopathologic signs of sepsis and septic shock | Markers of inflammation (CRP, IL-6) Host responsiveness (ICAM-1, cortisol, LBP) Specific targets of therapy (APC) |
Organ dysfunction | Clinicopathologic abnormalities suggesting organ dysfunction Number of failing organ systems | Measures of cellular response to insult or infection (cytopathic hypoxia, apoptosis) |
APC, Activated protein C; CRP, C-reactive protein; DNA, deoxyribonucleic acid; ICAM-1, intercellular adhesion molecule-1; IL-6, interleukin-6; LBP, lipopolysaccharide-binding protein; LPS, lipopolysaccharide; SIRS, systemic inflammatory response syndrome.